- Home
- DSGN vs CRDF Comparison
DSGN vs CRDF Comparison
Compare DSGN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- CRDF
- Stock Information
- Founded
- DSGN 2017
- CRDF 1999
- Country
- DSGN United States
- CRDF United States
- Employees
- DSGN N/A
- CRDF N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DSGN Health Care
- CRDF Health Care
- Exchange
- DSGN Nasdaq
- CRDF Nasdaq
- Market Cap
- DSGN 208.9M
- CRDF 233.5M
- IPO Year
- DSGN 2021
- CRDF N/A
- Fundamental
- Price
- DSGN $3.87
- CRDF $2.37
- Analyst Decision
- DSGN Hold
- CRDF Strong Buy
- Analyst Count
- DSGN 1
- CRDF 6
- Target Price
- DSGN $4.00
- CRDF $11.92
- AVG Volume (30 Days)
- DSGN 92.9K
- CRDF 2.8M
- Earning Date
- DSGN 08-12-2025
- CRDF 07-29-2025
- Dividend Yield
- DSGN N/A
- CRDF N/A
- EPS Growth
- DSGN N/A
- CRDF N/A
- EPS
- DSGN N/A
- CRDF N/A
- Revenue
- DSGN N/A
- CRDF $545,000.00
- Revenue This Year
- DSGN N/A
- CRDF N/A
- Revenue Next Year
- DSGN N/A
- CRDF N/A
- P/E Ratio
- DSGN N/A
- CRDF N/A
- Revenue Growth
- DSGN N/A
- CRDF N/A
- 52 Week Low
- DSGN $2.60
- CRDF $2.01
- 52 Week High
- DSGN $7.77
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- DSGN 47.12
- CRDF 28.67
- Support Level
- DSGN $3.89
- CRDF $3.73
- Resistance Level
- DSGN $4.19
- CRDF $4.52
- Average True Range (ATR)
- DSGN 0.23
- CRDF 0.35
- MACD
- DSGN -0.02
- CRDF -0.21
- Stochastic Oscillator
- DSGN 16.18
- CRDF 2.67
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.